BeStock  
Stocks › Biotechnology › ACAD

ACADIA Pharmaceuticals ACAD

US equityMarket cap rank #2441Biotechnology
$17.11 −$0.48 (-2.73%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $17.12 +0.06%
Open$17.47
Prev close$17.59
Day range$17.05 – $17.79
Volume1.90M
Market cap$2.96B
P/E (TTM)8.1
Dividend yield–

Earnings

Average move on report day±6.5%last 16 reports
Closed higher8 of 1650% of the time
Best reaction+14.3%
Worst reaction-19.5%

Stock move on the day after each report

-9.9%2023/Q4-11.2%2024/Q1-19.5%2024/Q2+8.9%2024/Q3+1.8%2024/Q4+14.3%2025/Q1+2.5%2025/Q2-3.0%2025/Q3-1.3%2025/Q4+5.0%2026/Q1+6.1%2026/Q2-1.1%2026/Q3
QuarterReport dateTimingImplied moveActual moveVersus implied
2026/Q34 Nov 2026After Market±6.5%-1.07%Within range
2026/Q24 Aug 2026After Market±9.6%+6.08%Within range
2026/Q16 May 2026After Market±7.1%+5.03%Within range
2025/Q425 Feb 2026After Market±9.5%-1.32%Within range
2025/Q35 Nov 2025After Market±12.7%-3.05%Within range
2025/Q26 Aug 2025After Market±10.6%+2.52%Within range
2025/Q17 May 2025After Market±13.2%+14.31%Bigger than priced
2024/Q426 Feb 2025After Market±14.0%+1.79%Within range
2024/Q36 Nov 2024After Market±15.8%+8.93%Within range
2024/Q26 Aug 2024After Market±20.4%-19.52%Within range
2024/Q18 May 2024After Market±17.3%-11.21%Within range
2023/Q427 Feb 2024After Market±15.3%-9.92%Within range
2023/Q32 Nov 2023After Market±10.3%+4.70%Within range
2023/Q22 Aug 2023After Market±8.8%-6.85%Within range
2023/Q18 May 2023After Market±10.3%-0.56%Within range
2022/Q427 Feb 2023After Market±16.9%+6.65%Within range

"Implied move" is the size of move the options market was pricing ahead of the report. Move is the stock’s change on the first session after the release.

Where the revenue comes from

Quarter 2026/Q3

By business line

  • NUPLAZID$202.16M 59.1%
  • DAYBUE$140.13M 40.9%

Latest reported quarter: Q3, ended Sep 2026

Revenue$342.29M+22.8% YoY
Operating profit$71.72M+100.6% YoY
Net profit$53.52M-25.4% YoY
Diluted EPS$0.31-26.2% YoY
Free cash flow$10.26M+141.2% YoY
Operating cash flow$11.50M

Revenue, last 8 quarters

$259.6MDec '24$244.3MMar '25$264.6MJun '25$278.6MSep '25$284.0MDec '25$268.1MMar '26$308.0MJun '26$342.3MSep '26

Net profit, last 8 quarters

$143.7MDec '24$19.0MMar '25$26.7MJun '25$71.8MSep '25$273.6MDec '25$3.6MMar '26$31.5MJun '26$53.5MSep '26

Profitability & balance sheet

Gross margin90.5%
Operating margin10.2%
Net margin30.1%
Return on equity31.4%
Return on assets23.2%
Return on invested capital28.2%
Current ratio3.82
Liabilities / assets22.7%
Cash & investments$976.45M
Total debt$57.32M
Net cash (debt)$919.12M
Free cash flow / sales15.0%

Discussion

No comments yet — be the first to weigh in on ACAD.

Sign in to join the discussion.

Scroll to Top